Prof Stephen Sawcer, MS Collaborator

My work with Genuity Science began in 2018, when we agreed to partner on a large Multiple Sclerosis (MS) genetic research study. Over the past 2 years we have sequenced the genomes of a significant number of participants who have taken part in the MS study that has been running at Cambridge University for many years. This work has been highly efficient and productive, and our joint efforts continue to evolve and grow. The next step is the analysis of the genomic data generated aiming to identify new targets that could be used in the treatment of MS.

I have been invited to attend, and on occasion speak, at MS-related information events and seminars held by Genuity. I also sit on their MS Scientific Advisory Board which helps to steer the scientific direction of the MS research.

Genuity’s commitment to improving the lives of patients is evident from their resolve to partner with collaborators and build a large research genomic database to further the development of new treatments for many complex and rare diseases. I have thoroughly enjoyed working with them and would happily collaborate with them on any other project in the future.

Professor Stephen Sawcer, University of Cambridge, Dept. of Clinical Neurosciences
Stephen Sawcer is Professor of Neurological Genetics at the University of Cambridge and an Honorary Consultant Neurologist at Addenbrooke’s Hospital. He completed a BSc in Physics at Liverpool University before going to medical school (MB ChB) at Birmingham University. He became MRCP in 1991 and FRCP in 2010. His PhD was undertaken at the University of Cambridge and was supervised by Professor Alastair Compston and Professor Peter Goodfellow. Professor Sawcer has worked on the genetics of multiple sclerosis for more than 20 years with a main focus on genomewide approaches, which involve rapid analysis of the genomes of a population with MS and looking for genetic markers that can be used to predict the presence of the disease. He is a member of the International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium (WTCCC)